Quest Diagnostics takes AmeriPath
This article was originally published in The Gray Sheet
Executive Summary
Quest expands its diagnostic testing services franchise through the purchase of AmeriPath, valued at $2 billion - or about 2.5 times AmeriPath annual sales. Announced April 16, the cash deal gives Quest a "leading position in cancer diagnostics with a focus on dermatopathology, anatomic pathology and molecular diagnostics," Quest maintains. "The joining together of our companies will facilitate and accelerate our mission of becoming the leader in the innovative delivery of quality pathology disease management services," AmeriPath says...